Results 21 to 30 of about 57,349 (269)

Self-Amplifying RNA Approach for Protein Replacement Therapy. [PDF]

Int J Mol Sci, 2022
Messenger RNA (mRNA) technology has already been successfully tested preclinically and there are ongoing clinical trials for protein replacement purposes; however, more effort has been put into the development of prevention strategies against infectious diseases.
Papukashvili D, Rcheulishvili N, Liu C, Ji Y, He Y, Wang PG.   +5 more
europepmc   +3 more sources

Delivery of self-amplifying RNA vaccines in in vitro reconstituted virus-like particles.

PLoS ONE, 2019
Many mRNA-based vaccines have been investigated for their specific potential to activate dendritic cells (DCs), the highly-specialized antigen-presenting cells of the immune system that play a key role in inducing effective CD4+ and CD8+ T-cell responses.
Adam Biddlecome, Habtom H Habte, Katherine M McGrath, Sharmila Sambanthamoorthy, Melanie Wurm, Martina M Sykora, Charles M Knobler, Ivo C Lorenz, Marcio Lasaro, Knut Elbers, William M Gelbart   +10 more
doaj   +3 more sources

The role of helper lipids in optimising nanoparticle formulations of self-amplifying RNA

Journal of Controlled Release
Lipid nanoparticle (LNP) formulation plays a vital role in RNA vaccine delivery. However, further optimisation of self-amplifying RNA (saRNA) vaccine formulation could help enhance seroconversion rates in humans and improve storage stability. Altering either the ionisable or helper lipid can alter the characteristics and performance of formulated saRNA
Barbieri, BD, Peeler, DJ, Samnuan, K, Day, S, Hu, K, Sallah, HJ, Tregoning, JS, McKay, PF, Shattock, RJ   +8 more
openaire   +5 more sources

Self-amplifying RNA vaccines for infectious diseases. [PDF]

Gene Ther, 2021
Vaccinology is shifting toward synthetic RNA platforms which allow for rapid, scalable, and cell-free manufacturing of prophylactic and therapeutic vaccines. The simple development pipeline is based on in vitro transcription of antigen-encoding sequences or immunotherapies as synthetic RNA transcripts, which are then formulated for delivery.
Bloom K, van den Berg F, Arbuthnot P.
europepmc   +4 more sources

Reinventing the nucleic acid vaccine with self-amplifying RNA [PDF]

Retrovirology, 2012
Background Self-amplifying RNAs (replicons) of positive-strand viruses such as alphaviruses are potentially safe and useful vectors for delivering vaccine antigens. We previously showed that recombinant alphavirus replicon particles (VRP), used in prime-boost regimen with Env in MF59 protein protected rhesus macaques against mucosal challenge with ...
Geall AJ, Otten GR, Hekele A, Bogers W, Oostermeijer H, Mooij P, Gerrit K, Verschoor E, Banerjee K, Cu Y, Beard CW, Brito LA, Ulmer JB, Mandl CW, Barnett SW   +14 more
doaj   +2 more sources

In Vitro Transcribed RNA-Based Platform Vaccines: Past, Present, and Future

Vaccines, 2023
mRNA was discovered in 1961, but it was not used as a vaccine until after three decades. Recently, the development of mRNA vaccine technology gained great impetus from the pursuit of vaccines against COVID-19.
Alexey D. Perenkov, Alena D. Sergeeva, Maria V. Vedunova, Dmitri V. Krysko   +3 more
doaj   +1 more source

RNA Combined with Nanoformulation to Advance Therapeutic Technologies

Pharmaceuticals, 2023
Nucleic acid-based therapies have the potential to address numerous diseases that pose significant challenges to more traditional methods. RNA-based therapies have emerged as a promising avenue, utilizing nanoformulation treatments to target a range of ...
Eduarda Santos Lima, Déborah dos Santos, Atena Liriel Souza, Maria Eduarda Macedo, Mariana Evangelista Bandeira, Sérgio Santos Silva Junior, Bianca Sampaio Dotto Fiuza, Vinicius Pinto Costa Rocha, Larissa Moraes dos Santos Fonseca, Danielle Devequi Gomes Nunes, Katharine Valéria Saraiva Hodel, Bruna Aparecida Souza Machado   +11 more
doaj   +1 more source

An Update on Self-Amplifying mRNA Vaccine Development

Vaccines, 2021
This review will explore the four major pillars required for design and development of an saRNA vaccine: Antigen design, vector design, non-viral delivery systems, and manufacturing (both saRNA and lipid nanoparticles (LNP)).
Anna K. Blakney, Shell Ip, Andrew J. Geall   +2 more
doaj   +1 more source

Self-amplifying RNA vaccine protects mice against lethal Ebola virus infection. [PDF]

Mol Ther, 2023
Emerging and re-emerging viruses, such as Zaire Ebola virus (EBOV), pose a global threat and require immediate countermeasures, including the rapid development of effective vaccines that are easy to manufacture. Synthetic self-amplifying RNAs (saRNAs) attend to these needs, being safe and strong immune stimulators that can be inexpensively produced in ...
Krähling V, Erbar S, Kupke A, Nogueira SS, Walzer KC, Berger H, Dietzel E, Halwe S, Rohde C, Sauerhering L, Aragão-Santiago L, Moreno Herrero J, Witzel S, Haas H, Becker S, Sahin U.   +15 more
europepmc   +3 more sources

Conjugation of Mannans to Enhance the Potency of Liposome Nanoparticles for the Delivery of RNA Vaccines

Pharmaceutics, 2021
Recent approval of mRNA vaccines to combat COVID-19 have highlighted the potential of this platform. Lipid nanoparticles (LNP) is the delivery vehicle of choice for mRNA as they prevent its enzymatic degradation by encapsulation.
Roshan Goswami, Derek T. O’Hagan, Roberto Adamo, Barbara C. Baudner   +3 more
doaj   +1 more source